Vicore Pharma AB
Anne Katrine Cohrt is an accomplished professional in the field of clinical operations, currently serving as Sr. Director and Head of Clinical Operations at Vicore Pharma AB since June 2020. With a robust background that includes roles such as International Clinical Project Director and International Clinical Trial Manager at Pharmacosmos, Clinical Project Manager at ALK, and Clinical Operations Manager at LifeCycle Pharma/Veloxis, Anne Katrine has demonstrated extensive expertise in managing clinical projects and operations. Prior experience includes positions at aCROnordic ApS as Team Leader and Clinical Research Associate, regulatory affairs at Novo Nordisk, and a Clinical Research Associate role at Merck. Anne Katrine Cohrt holds a Master of Science in Pharmacy from Københavns Universitet - University of Copenhagen, earned from 1996 to 2002.
This person is not in any teams
This person is not in any offices
Vicore Pharma AB
1 followers
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.